NUCLEAR MEDICINE QUALITY CONSULTING ApS

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
Loading...

Loading...

Loading...

Loading...

Loading...

Loading...

Loading...

Bankruptcy Risk 
2016
2016/8
2017
2017/8
2018
2018/8
2019
2019/8
2020
2020/8
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  14.5% 16.8% 15.1% 17.0% 18.3%  
Credit score (0-100)  17 12 14 10 8  
Credit rating  BB BB BB BB B  
Credit limit (kDKK)  0.0 0.0 0.0 0.0 0.0  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2016
2016/8
2017
2017/8
2018
2018/8
2019
2019/8
2020
2020/8

Net sales  63 0 36 65 0  
Gross profit  63.0 0.0 35.6 64.3 -1.2  
EBITDA  62.6 -0.3 35.6 64.3 -1.2  
EBIT  62.6 -0.3 35.6 64.3 -1.2  
Pre-tax profit (PTP)  62.6 -0.3 35.6 64.3 -1.2  
Net earnings  50.7 -0.3 27.8 50.1 -1.2  
Pre-tax profit without non-rec. items  62.6 -0.3 35.6 64.3 -1.2  

 
See the entire income statement

Balance sheet (kDKK) 
2016
2016/8
2017
2017/8
2018
2018/8
2019
2019/8
2020
2020/8

Tangible assets total  0.0 0.0 0.0 0.0 0.0  
Shareholders equity total  126 81.6 109 92.4 91.2  
Interest-bearing liabilities  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  149 81.6 117 94.4 91.2  

Net Debt  -116 -76.6 -112 -89.4 -86.2  
 
See the entire balance sheet

Volume 
2016
2016/8
2017
2017/8
2018
2018/8
2019
2019/8
2020
2020/8

Net sales  63 0 36 65 0  
Net sales growth  0.0% -100.0% 0.0% 80.6% -100.0%  
Gross profit  63.0 0.0 35.6 64.3 -1.2  
Gross profit growth  0.0% -100.0% 0.0% 80.4% 0.0%  
Employees  0 0 0 0 0  
Employee growth %  0.0% 0.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  149 82 117 94 91  
Balance sheet change%  0.0% -45.2% 43.6% -19.4% -3.4%  
Added value  62.6 -0.3 35.6 64.3 -1.2  
Added value %  99.4% 0.0% 99.0% 98.9% 0.0%  
Investments  0 0 0 0 0  

Net sales trend  0.0 -1.0 0.0 1.0 -1.0  
EBIT trend  1.0 -1.0 1.0 2.0 -1.0  

Profitability 
2016
2016/8
2017
2017/8
2018
2018/8
2019
2019/8
2020
2020/8
EBITDA %  99.4% 0.0% 99.0% 98.9% 0.0%  
EBIT %  99.4% 0.0% 99.0% 98.9% 0.0%  
EBIT to gross profit (%)  99.4% 0.0% 100.0% 100.0% 100.0%  
Net Earnings %  80.4% 0.0% 77.2% 77.1% 0.0%  
Profit before depreciation and extraordinary items %  80.4% 0.0% 77.2% 77.1% 0.0%  
Pre tax profit less extraordinaries %  99.4% 0.0% 99.0% 98.9% 0.0%  
ROA %  42.0% -0.2% 35.9% 60.8% -1.3%  
ROI %  42.0% -0.2% 37.3% 63.7% -1.3%  
ROE %  40.3% -0.3% 29.1% 49.7% -1.3%  

Solidity 
2016
2016/8
2017
2017/8
2018
2018/8
2019
2019/8
2020
2020/8
Equity ratio %  84.4% 100.0% 93.3% 97.9% 100.0%  
Relative indebtedness %  0.0% 0.0% 21.8% 3.0% 0.0%  
Relative net indebtedness %  -184.0% 0.0% -289.6% -134.5% 0.0%  
Net int. bear. debt to EBITDA, %  -185.2% 29,222.5% -314.7% -139.1% 7,359.4%  
Gearing %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 0.0% 0.0% 0.0% 0.0%  

Liquidity 
2016
2016/8
2017
2017/8
2018
2018/8
2019
2019/8
2020
2020/8
Quick Ratio  0.0 0.0 14.9 47.8 0.0  
Current Ratio  0.0 0.0 14.9 47.8 0.0  
Cash and cash equivalent  115.9 76.6 112.1 89.4 86.2  

Capital use efficiency 
2016
2016/8
2017
2017/8
2018
2018/8
2019
2019/8
2020
2020/8
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  236.4% 0.0% 325.3% 145.2% 0.0%  
Net working capital  148.9 81.6 109.3 92.4 91.2  
Net working capital %  236.4% 0.0% 303.5% 142.1% 0.0%  

Employee efficiency 
2016
2016/8
2017
2017/8
2018
2018/8
2019
2019/8
2020
2020/8
Net sales / employee  0 0 0 0 0  
Added value / employee  0 0 0 0 0  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 0 0 0 0  
EBIT / employee  0 0 0 0 0  
Net earnings / employee  0 0 0 0 0